Neural therapy for fibromyalgia: Myth or improving quality of life?

Basit Öğe Kaydı
dc.authoridBalevi Batur, Elif / 0000-0001-8886-1144
dc.authoridAtan, Tuğba / 0000-0003-1229-8679
dc.authorscopusid57201903686
dc.authorscopusid55986316300
dc.contributor.authorBalevi Batur, Elif
dc.contributor.authorAtan, Tuğba
dc.date.accessioned2021-11-01T14:51:34Z
dc.date.available2021-11-01T14:51:34Z
dc.date.issued2021
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractBackground: Fibromyalgia is a common rheumatic disease, which is thought to be a neuroendocrine dysregulation disorder. Patients’ quality of life (QOL) is severely affected by this disease. Though neural therapy, as a treatment option, attempts to correct the underlying neuroendocrine dysfunction, yet there is no proven evidence of its effect on this disease. The present study aimed to evaluate the effectiveness of neural therapy on pain and functionality in patients with fibromyalgia. Methods: The study was a 1-year retrospective cohort study and held in physical medicine and rehabilitation clinics. A total of 60 female patients diagnosed with fibromyalgia were included. Sixty female patients with fibromyalgia were included in this study. Patients were divided into two groups; the first group (n = 30) received neural therapy, the second group (n = 30) received conventional physical therapy and each of the two groups received the same home exercise (stretching, strengthening and aerobic exercises) programme for four weeks. The primer outcomes were visual analogue scale (VAS), Short Form-36 (SF-36) and Fibromyalgia Impact Questionnaire (FIQ) scores after the treatment. Results: The social functioning score exhibited a significant improvement only in the intra-group comparison of the neural therapy group (P <.001). However, after treatment, the VAS, FIQ and all the SF-36 parameters, except role limitations because of physical health, were detected to be significantly improved in the neural therapy group compared with the exercise group (P <.001). Conclusions: Neural therapy may be an effective alternative treatment for improving the QOL in patients with fibromyalgia. © 2020 John Wiley & Sons Ltd
dc.identifier.citationBalevi Batur, E., & Atan, T. (2021). Neural therapy for fibromyalgia: Myth or improving quality of life?. International Journal of Clinical Practice, 75(4), e13719.
dc.identifier.doi10.1111/ijcp.13719
dc.identifier.issn1368-5031
dc.identifier.issue4en_US
dc.identifier.pmid32955788
dc.identifier.scopus2-s2.0-85097832903
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1111/ijcp.13719
dc.identifier.urihttps://hdl.handle.net/11491/6179
dc.identifier.volume75en_US
dc.identifier.wosWOS:000600513100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAtan, Tuğba
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofInternational Journal of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleNeural therapy for fibromyalgia: Myth or improving quality of life?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu